Dr. Spector is a co-founder of SFA Therapeutics, a microbiome-derived biopharm company focused on new advancements in the treatment inflammatory diseases.
Ira is an experienced drug developer, with over 30 years of experience. He has helped develop 34 approved drugs, including Enbrel, Effexor, Protonix, Prevenar-13, Mylotarg at Wyeth/Pfizer, where he was Vice President of Clinical Operations and Vice-Chief of Development. At Allergan he helped develop Ozurdex for Diabetic Macular Edema and Retinal Venous Occlusion, Botox for Overactive Bladder, Botox for Chronic Migraine, Juvederm XL and Botox for Cerebral Palsy. Prior to Wyeth, he was Vice President and Partner at the PA Consulting Group. Before founding SFA Therapeutics, Ira was Executive Vice President of Analytics & Consulting at ICON.
Ira holds BS degrees in Physics and Electrical Engineering from Washington University, where he was a Langsdorf Fellow, an MBA from Drexel University, and a PhD in Health Sciences from UMDNJ.
Ira is an experienced drug developer, with over 30 years of experience. He has helped develop 34 approved drugs, including Enbrel, Effexor, Protonix, Prevenar-13, Mylotarg at Wyeth/Pfizer, where he was Vice President of Clinical Operations and Vice-Chief of Development. At Allergan he helped develop Ozurdex for Diabetic Macular Edema and Retinal Venous Occlusion, Botox for Overactive Bladder, Botox for Chronic Migraine, Juvederm XL and Botox for Cerebral Palsy. Prior to Wyeth, he was Vice President and Partner at the PA Consulting Group. Before founding SFA Therapeutics, Ira was Executive Vice President of Analytics & Consulting at ICON.
Ira holds BS degrees in Physics and Electrical Engineering from Washington University, where he was a Langsdorf Fellow, an MBA from Drexel University, and a PhD in Health Sciences from UMDNJ.
Speaking In
[Company Presentations]
SFA Therapeutics is a clinical-stage oral small molecule, novel immunomodulatory focused company…